Trial Profile
An Open-label, Single-arm Study to Characterize the Pharmacodynamics and Safety of Repeat Dose SP-102 Administered by Epidural Injection in Subjects With Lumbosacral Radiculopathy
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 10 Jan 2019
At a glance
- Drugs SP 102 (Primary)
- Indications Sciatica
- Focus Pharmacodynamics
- Sponsors Semnur Pharmaceuticals
- 07 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 10 Aug 2018 New trial record